CSIMarket Company Name, Ticker, Industry, else..
 
Nuwellis Inc   (NASDAQ: NUWE)
Other Ticker:  
 
 
Price: $1.2100 $0.13 11.521%
Day's High: $1.2294 Week Perf: 19.8 %
Day's Low: $ 1.06 30 Day Perf: 1.68 %
Volume (M): 456 52 Wk High: $ 27.61
Volume (M$): $ 552 52 Wk Avg: $6.75
Open: $1.07 52 Wk Low: $0.92



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 0
 Employees 50
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Nuwellis Inc
Nuwellis Inc is a medical device company that specializes in developing and commercializing innovative therapies for patients with chronic heart failure and other fluid overload conditions. The company's flagship product, known as the Aquadex FlexFlow System, is a fluid management system that utilizes ultrafiltration to safely remove excess fluid from patients. This portable system allows patients to manage their fluid balance at home, reducing the need for hospitalization and improving their quality of life. Nuwellis Inc is dedicated to improving patient outcomes and creating more cost-effective solutions for fluid management in the healthcare industry.


   Company Address: 12988 Valley View Road Eden Prairie 55344 MN
   Company Phone Number: 345-4200   Stock Exchange / Ticker: NASDAQ NUWE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CNMD   -2.6%    
ENOV        2.82% 
IART        8.12% 
MDT        7.69% 
SYK        6.22% 
ZBH        3.86% 
• View Complete Report
   



Shares

Nuwellis Secures $5.1 Million Fundraising Through Warrant Exercises, Bolstering Path to Sustain Nasdaq Listing

Published Tue, Nov 5 2024 2:28 PM UTC

On November 5, 2024, Minneapolis-based Nuwellis, Inc. (Nasdaq: NUWE), a prominent player in the medical technology sector, notably specializing in solutions for fluid overload, announced a significant financial milestone. The company revealed the immediate exercise of certain warrants, yielding approximately $5.1 million in gross proceeds.The warrants exercised consist of ap...
Management Announcement

Nuwellis Bold Leap: Medicare Reimbursement Surge Amid Struggling ROI Performance

Published Mon, Nov 4 2024 1:30 PM UTC

In a move destined to reshape its financial outlook, Nuwellis Inc. announced a staggering 397% daily increase in the reimbursement rate for its Aquadex SmartFlow Therapy, effective January 1, 2025, from the Centers for Medicare and Medicaid Services (CMS). This monumental improvement comes on the heels of a more modest, but still impressive, 112.88% increase over the trailin...
Stock Market Announcement

Nuwellis Announces At-The-Market Offering and Receives Continued Listing Approval on Nasdaq

Published Fri, Aug 23 2024 1:00 PM UTC



In a recent press release, medical technology company Nuwellis, Inc. (Nasdaq: NUWE) has revealed its entry into a definitive securities purchase agreement with select institutional investors. Under this agreement, Nuwellis will undertake a registered direct offering priced at-the-market under Nasdaq rules. The offering will consist of 496,901 shares of the Company ...
Stock Market Announcement

Nuwellis, Inc. Successfully Extends Nasdaq Listing, Paving the Way for Transformative Fluid Overload Treatment Innovations

Published Thu, Aug 8 2024 1:00 PM UTC



MINNEAPOLIS, Aug. 08, 2024 - Nuwellis, Inc. (Nasdaq: NUWE), a prominent medical technology company dedicated to revolutionizing the lives of individuals suffering from fluid overload, excitedly announced today that The Nasdaq Hearings Panel (Panel) has granted its request to extend its listing on the Nasdaq Stock Market. This decision comes with certain conditions ...
Clinical Study

First Pediatric Patient Treated with QUELIMMUNE Therapy for Acute Kidney Injury and Sepsis at Cincinnati Childrens H...

Published Fri, Jul 26 2024 1:00 PM UTC

Abstract A recent groundbreaking medical milestone has been achieved in pediatric care with the first commercial use of SeaStar Medical s QUELIMMUNE therapy, administered at Cincinnati Children s Hospital. This innovative treatment, exclusively distributed in U.S. pediatric hospitals by Nuwellis, Inc., is poised to transform the management of acute kidney injury (AKI) compli...






Nuwellis Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com